Biogen’s aducanumab has been praised before a final approval meeting by the U.S. Food and Drug Administration (FDA) to treat the disease that is the sixth leading case of death among 65+, Alzheimer’s. Biogen is expecting “blockbuster” sales of over $1 billion from the drug designed to remove amyloid plaques from the brain.  Biogen is a company that specializes in treatments for neurological disorders and is among other companies to release treatments for Alzheimer’s, but Biogen’s drug is the only one with proven efficacy in altering the ravaging course of the illness.

Read more here.  

More on: